Benzinga | Aug 24, 2021 07:03AM EDT

Cowen & Co. Downgrades Theravance Biopharma to Market Perform, Lowers Price Target to $14

Cowen & Co. analyst Marc Frahm downgrades Theravance Biopharma (NASDAQ:TBPH) from Outperform to Market Perform and lowers the price target from $42 to $14.